Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)
研究概览
简要总结
This is a prospective, single arm, single center study to evaluate the efficacy and safety of Duvelisib combined with Chidamide in the treatment of newly diagnosed peripheral T-cell lymphoma.
详细描述
This is a prospective, single arm, single center study, including two phases. It plans to recruit36 patients with clinically diagnosed primary PTCL who will be treated with Duvelisib and Chidamide. In the first phase Duvelisib is Oral administration at a dose of 25mg twice a day, and every 4 weeks (28 days) was a cycle. Next administration will be depend on whether the efficacy reaches CR in the second phase.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Age: 18-70 Years (Contains boundary values 18 and 70);
- •2.The newly diagnosed PTCL confirmed by histopathology is one of the following subtypes;
- •a) Angioimmunoblastic T-cell lymphoma (AITL); b) Follicular T helper cell lymphoma (T-FHCL); Including but not limited to the above two subtypes;
- •3.ECOG ≤ 3;
- •4.At least one measurable or evaluable tumor lesion according to the Lugano-2014 standard;
- •5.Expected survival ≥ 3 months;
- •6.Subjects fully understand and voluntarily participate in this study and sign informed consent;
排除标准
- •1.Subjects who have previously received systemic treatment for lymphoma or currently undergoing anticancer treatment;
- •2.Subjects with central nervous system (CNS) lymphoma or lymphoma involving CNS;
- •3.Significant active heart disease within the past 6 months, including: New York Heart Association (NYHA) Class III/IV congestive heart failure unstable angina pectoris or angina requiring surgical or medication intervention, and/or myocardial infarction;
- •4.Uncontrolled systemic fungal, bacterial, or viral infections (defined as persistent signs/symptoms related to infection that have not improved despite the use of appropriate antibiotics, antiviral therapy, and/or other treatments);
- •5.Human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection and history of severe skin reaction;
- •6.Subjects with any other active malignant tumor at the time of screening, except for adequately treated cervical Carcinoma in situ or breast cancer Carcinoma in situ, skin Basal-cell carcinoma or local skin squamous cell carcinoma;
- •7.Pregnant women, lactating women, patients who refused to take effective contraceptive measures during the study;
- •8.Any serious uncontrolled systemic disease;
- •9.increasing the risk of the subject or interfering with the test results determined by the investigator;
研究组 & 干预措施
Duvelisib-Chidamide
Patients with newly diagnosed PTCL were treated with a combination of Duvelisib and Chidamide. The dose of Duvelisib was 25mg twice a day. Every 4 weeks (28 days) is a cycle with a total of 2 cycles.
干预措施: Duvelisib, Chidamide (Drug)
结局指标
主要结局
Safety: Hematologic and non-hematologic toxicities (NCI CTCAE v5.0)
时间窗: from the initiation of the first dose to 28 days after the last dose
To identify the incidence of AE and SAE in clinical trial
次要结局
- Objective response rate (ORR)(up to 26 weeks)
- Complete remission rate (CR)(up to 26 weeks)
- Progression free survival (PFS)(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months)
- Overall survival (OS)(From date of randomization until the date of death from any cause, assessed up to 20 months)
- Duration of Response（DOR）(The time from the first assessment as CR or PR to the first assessment as PD or death (due to any cause)，assessed up to 12 months)
研究者
Liling Zhang
chief physician
Huazhong University of Science and Technology